Ensysce Biosciences (ENSCW) EBT Margin (2020 - 2025)
Ensysce Biosciences (ENSCW) reported EBT Margin of 759.97% for Q3 2025, down 77871.0% year-over-year from N/an in Q3 2024, and down 494.33% quarter-over-quarter from 127.87% in Q2 2025.
Ensysce Biosciences (ENSCW) EBT Margin (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 6 years of EBT Margin data on file, last reported at 759.97% in Q3 2025.
- EBT Margin for Q3 2025 came in at 759.97%, down 77871.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 246.23% (down 6679.0% YoY), and the FY2024 annual result was 153.78%, up 34262.0% from the prior year.
- EBT Margin eased to 759.97% in Q3 2025 per ENSCW's latest filing, from 127.87% in the prior quarter.
- Over five years, EBT Margin peaked at 18.74% in Q3 2024 and troughed at 3418.77% in Q2 2022.
- A 5-year average of 783.46% and a median of 623.58% in 2023 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2023: EBT Margin plunged 312116 bps in 2022, then jumped 295107 bps in 2023.
- A 5-year view of EBT Margin shows it stood at 123.48% in 2021, then tumbled by 250 bps to 432.79% in 2022, then sank by 57 bps to 679.66% in 2023, then surged by 60 bps to 274.49% in 2024, then sank by 177 bps to 759.97% in 2025.
- Business Quant data shows ENSCW's EBT Margin at 759.97% in Q3 2025, 127.87% in Q2 2025, and 149.37% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -759.97% |
| Jun 30, 2025 | -127.87% |
| Mar 31, 2025 | -149.37% |
| Dec 31, 2024 | -274.49% |
| Sep 30, 2024 | 18.74% |
| Jun 30, 2024 | -1,090.78% |
| Mar 31, 2024 | -1,011.06% |
| Dec 31, 2023 | -679.66% |
| Sep 30, 2023 | -623.58% |
| Jun 30, 2023 | -467.70% |
| Mar 31, 2023 | -324.55% |
| Dec 31, 2022 | -432.79% |
| Sep 30, 2022 | -2,208.04% |
| Jun 30, 2022 | -3,418.77% |
| Mar 31, 2022 | -798.85% |
| Dec 31, 2021 | -123.48% |
| Sep 30, 2021 | -1,408.33% |
| Jun 30, 2021 | -297.61% |
| Mar 31, 2021 | -707.52% |
| Dec 31, 2020 | -322.05% |